A combination of electrochemotherapy, gene electrotransfer of plasmid encoding canine IL-12 and cytoreductive surgery in the treatment of canine oral malignant melanoma

Milevoj, Nina (avtor), Lampreht Tratar, Urša (avtor), Nemec, Ana (avtor), Brožič, Andreja (avtor), Žnidar, Katarina (avtor), Serša, Gregor (avtor), Čemažar, Maja (avtor), Tozon, Nataša (avtor)

The aim of this study was to evaluate the safety and efficacy of the combination of electrochemotherapy (ECT) with bleomycin and gene electrotransfer (GET) of plasmid encoding canine interleukin 12 (IL-12) for the treatment of canine oral malignant melanoma (OMM). Our focus was to determine the effect of the treatment on achieving local tumor control and stimulation of an antitumor immune response. Nine dogs with histologically confirmed OMM stage I to III were included in a prospective, non-randomized study. The dogs were treated with a combination of cytoreductive surgery, ECT and IL-12 GET, which was repeated up to five times, depending on the clinical response to the treatment, evaluated according to the follow-up protocol (7, 14 and 28 days after, the last treatment). One month after treatment, the objective response (OR) rate was 67% (6/9). Median survival time (MST) was 6 months and, even though the disease progressed in 8/9 patients at the end of the observation period (2 to 22 months), four animals were euthanized due to tumor-unrelated reasons. In addition, we observed a decline in the percentage of regulatory T cells (Treg) in the peripheral blood in the course of the treatment, which could be attributed to a systemic antitumor response to IL-12 GET. The results of this study suggest that a combination of ECT and IL-12 GET may be beneficial for dogs with OMM, especially when other treatment approaches are not acceptable due to their invasiveness or cost.

• Jezik: Angleški jezik
• Ključne besede: electrochemotherapy, surgery, oral, interleukin-12, cytoreductive surgery, oral malignant melanoma, regulatory T cells, dogs
• Vrsta gradiva: Znanstveno delo
• Tipologija: 1.01 - Izvirni znanstveni članek
• Organizacija: VF - Veterinarska fakulteta
• Status publikacije: Objavljeno
• Različica publikacije: Recenzirani rokopis
• Založnik: Elsevier
• Leto izida: 2019
• Št. strani: Str. 40-49
• Številčenje: Vol. 122
• PID: 20.500.12556/RUL-108751
• UDK: 636.7.09:616-006:615
• ISSN pri članku: 0034-5288
• DOI: 10.1016/j.rvsc.2018.11.001
• COBISS.SI-ID: 4730490

Avtorske pravice

založnik

• Datum objave v RUL: 19.07.2019

Gradivo je del revije

• Naslov: Research in Veterinary Science
• Skrajšan naslov: Res. Vet. Sci.
• Založnik: British Veterinary Association
• ISSN: 0034-5288
• COBISS.SI-ID: 26274816

Licence

• Licenca: CC BY-NC-ND 4.0, Creative Commons Priznanje avtorstva-Nekomercialno-Brez predelav 4.0 Mednarodna
• Povezava: http://creativecommons.org/licenses/by-nc-nd/4.0/deed.sl
• Opis: Najbolj omejujoča licenca Creative Commons. Uporabniki lahko prenesejo in delijo delo v nekomercialne namene in ga ne smejo uporabiti za nobene druge namene.
• Začetek licenciranja: 19.07.2019

Sekundarni jezik

• Jezik: Ni določen
• Ključne besede: elektrokemoterapija, oralna kirurgija, interleukin-12, citoreduktivna kirurgija, oralni maligni melanom, regulatorne celice T, psi

Projekti

• Financer: ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
• Številka projekta: P3-0003, P4-0053
• Naslov: Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev; Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih; Translacijska onkologija: razvoj in validacija imunsko genske terapije z interleukinom-12 v kombinaciji s kirurgijo pri oralnih in kožnih tumorjih psov
• Akronim: J3-6796